
Soft Tissue Sarcoma Market Report and Forecast 2024-2032
Description
Soft Tissue Sarcoma Market Report and Forecast 2024-2032
Soft Tissue Sarcoma Market Report and Forecast 2024-2032
Soft Tissue Sarcoma Market Overview
The soft tissue sarcoma market size is expected to grow at a compound annual growth rate (CAGR) of 5.5% during the forecast period of 2024-2032. The major factors driving the market growth are the increasing incidence and prevalence of soft tissue sarcoma, the rising awareness and diagnosis of the disease, the development of novel and targeted therapies, and the increasing investment and funding for research and development. However, the market growth is hampered by the high cost and side effects of the treatments, the lack of specific biomarkers and screening tests, and the low survival rate of the patients.
Soft tissue sarcomas are rare malignant tumors that arise from the soft tissues of the body, such as fat, muscle, blood vessels, nerves, and connective tissues. They can occur in any part of the body, but most commonly affect the limbs, trunk, abdomen, and retroperitoneum.
Soft Tissue Sarcoma Market Drivers and Constraints
- The increasing incidence and prevalence of soft tissue sarcoma is one of the key drivers of the market growth. According to the GLOBOCAN 2020, there were an estimated 42,500 new cases and 18,900 deaths from soft tissue sarcoma worldwide in 2020. The incidence rate of soft tissue sarcoma varies by region, with the highest rates in North America and Europe, and the lowest rates in Africa and Asia. The prevalence of soft tissue sarcoma is also increasing due to the improved survival of the patients with the advent of new therapies and supportive care.
- The rising awareness and diagnosis of soft tissue sarcoma is another key driver of the market growth. Soft tissue sarcoma is often misdiagnosed or overlooked due to its rarity and nonspecific symptoms. However, the awareness of the disease and its risk factors, such as genetic syndromes, radiation exposure, and chemical exposure, is increasing among the general public and the healthcare professionals. Moreover, the diagnosis of soft tissue sarcoma is improving with the use of advanced imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), and the availability of specialized pathology and molecular testing.
- The development of novel and targeted therapies is a major driver of the market growth. The treatment of soft tissue sarcoma is challenging due to the heterogeneity and aggressiveness of the disease, the resistance to conventional chemotherapy and radiotherapy, and the limited options for metastatic or recurrent disease. However, the emergence of novel and targeted therapies, such as immunotherapy, tyrosine kinase inhibitors, antibody-drug conjugates, and gene therapy, has provided new hope and opportunities for the patients and the clinicians. These therapies have shown promising results in terms of efficacy, safety, and tolerability in various clinical trials and have received regulatory approvals or are in the pipeline for approval.
- The increasing investment and funding for research and development is a significant driver of the market growth. The research and development of soft tissue sarcoma is supported by various public and private organizations, such as the National Cancer Institute (NCI), the European Organisation for Research and Treatment of Cancer (EORTC), the Sarcoma Foundation of America (SFA), and the Liddy Shriver Sarcoma Initiative.
- The high cost and side effects of the treatments are the major constraints of the market growth. The treatment of soft tissue sarcoma is expensive and often requires multiple modalities, such as surgery, chemotherapy, radiotherapy, and targeted therapy. The cost of the treatment varies depending on the type, stage, and location of the tumor, the choice of the therapy, and the healthcare system of the country. The cost of the treatment can impose a significant financial burden on the patients and their families, as well as on the healthcare systems and the society. Moreover, the treatments of soft tissue sarcoma are associated with various side effects, such as nausea, vomiting, fatigue, hair loss, infection, bleeding, pain, nerve damage, lymphedema, and cardiotoxicity. These side effects can affect the quality of life and the compliance of the patients, as well as increase the risk of morbidity and mortality.
- The lack of specific biomarkers and screening tests is another constraint of market growth. Soft tissue sarcoma is a heterogeneous and complex disease with multiple subtypes and molecular alterations. However, there are no specific biomarkers or screening tests that can accurately detect, diagnose, classify, or predict the prognosis or response to the treatment of soft tissue sarcoma. The current diagnosis of soft tissue sarcoma relies on the histopathological and immunohistochemical examination of the tumor tissue, which can be subjective, inaccurate, or inconclusive. The lack of specific biomarkers and screening tests limits the early detection and prevention of the disease, as well as the development of personalized and precision medicine.
- The low survival rate of the patients is a further constraint of the market growth. Soft tissue sarcoma is a highly aggressive and metastatic disease with a poor prognosis. The survival rate of the patients depends on various factors, such as the type, stage, and location of the tumor, the age and health of the patient, and the availability and effectiveness of the treatment. According to the SEER data, the 5-year relative survival rate of soft tissue sarcoma in the United States is 65% for localized disease, 44% for regional disease, and 18% for distant disease. The low survival rate of the patients reduces the demand and the market potential for the treatments, as well as the incentive and the feasibility of the research and development.
The global soft tissue sarcoma market is witnessing significant growth, driven by increasing incidences of soft tissue sarcoma globally, advancements in medical treatments, and a growing awareness of the condition. The market is characterized by several key trends and developments that are shaping the landscape of diagnosis, treatment, and patient care in this sector.
- Innovation in Therapeutics: There is a noticeable trend towards the innovation in therapeutics, including targeted therapies and immunotherapies. These new treatment modalities offer hope for improved survival rates and quality of life for patients with soft tissue sarcoma. Pharmaceutical companies and research institutions are investing heavily in R&D to explore and develop these advanced treatment options. This includes efforts to understand the genetic and molecular basis of various types of sarcomas to develop more effective and personalized treatment plans.
- Diagnostic Advances: Advances in diagnostic technologies and methodologies are improving the early detection and characterization of soft tissue sarcomas. High-resolution imaging techniques, along with molecular and genetic testing, are becoming more prevalent. These advances facilitate more accurate diagnoses, enabling earlier and more targeted treatment interventions. Early diagnosis is critical in improving the prognosis for patients with soft tissue sarcoma.
- Regulatory Approvals: The global soft tissue sarcoma market has seen an increase in regulatory approvals for new treatments and drugs. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are recognizing the urgent need for new therapeutic options and are fast-tracking approval processes for promising drugs. This is encouraging for pharmaceutical companies and provides hope for patients seeking effective treatment options.
- Global Health Initiatives: There is a growing emphasis on global health initiatives aimed at increasing awareness and improving treatment outcomes for soft tissue sarcoma. Collaborations between governments, healthcare organizations, and non-profits are focusing on research funding, patient education, and access to care. These initiatives are crucial for addressing disparities in treatment access and outcomes, especially in underserved populations.
- Market Expansion and Challenges: The global soft tissue sarcoma market is expanding, with a notable increase in demand for treatments in emerging economies. However, the market faces challenges, including the high cost of new therapies and limited availability in some regions. Ensuring equitable access to advanced treatments remains a significant challenge that stakeholders are striving to address.
Soft Tissue Sarcoma Market Segmentation
Market Breakup by Treatment Type
- Radiation Therapy
- Anti-Angiogenesis
- Chemotherapy
- Targeted Therapy
- Others
- Oral
- Parenteral
- Others
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online pharmacy
- Others
- United States
- EU-4 and United Kingdom
- Germany
- France
- Italy
- Spain
- Kingdom
- Japan
- India
The soft tissue sarcoma market is characterized by the presence of several global and regional players, who compete on the basis of product portfolio, price, quality, and innovation. Some of the key players in this market are Endo International PLC, Dr. Reddy's Laboratories Ltd, and Lupin, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Merck & Co., Lilly, Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Mylan N.V., and F. Hoffmann-La Roche Ltd.
Endo International PLC is a leading specialty pharmaceutical company that offers a range of products for pain management, oncology, urology, and endocrinology. The company has a strong presence in the US and Europe, and markets its products under various brands, such as XIAFLEX, OPANA, and PERCOCET.
Table of Contents
160 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Soft Tissue Sarcoma Market Overview – 8 Major Markets
- 3.1 Soft Tissue Sarcoma Market Historical Value (2017-2023)
- 3.2 Soft Tissue Sarcoma Market Forecast Value (2024-2032)
- 4 Soft Tissue Sarcoma Overview
- 4.1 Guidelines and Stages
- 4.2 Pathophysiology
- 4.3 Screening and Diagnosis
- 4.4 Therapy Pathway
- 5 Patient Profile
- 5.1 Patient Profile Overview
- 5.2 Patient Psychology and Emotional Impact Factors
- 5.3 Risk Assessment and Therapy Success Rate
- 6 Soft Tissue Sarcoma Epidemiology Scenario and Forecast – 8 Major Markets
- 6.1 8MM Epidemiology Scenario Overview (2017-2032)
- 6.2 United States Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.3 EU-4 and United Kingdom Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.3.1 Germany Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.3.2 France Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.3.3 Italy Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.3.4 Spain Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.3.5 United Kingdom Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.4 Japan Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 6.5 India Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
- 7 Soft Tissue Sarcoma Market Landscape-8 Major Markets
- 7.1 Soft Tissue Sarcoma Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Soft Tissue Sarcoma Product Landscape
- 7.2.1 Analysis by Treatment Type
- 7.2.2 Analysis by Route of Administration
- 8 Soft Tissue Sarcoma Therapy Challenges and Unmet Needs
- 8.1 Therapy Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Therapy
- 10 Soft Tissue Sarcoma Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Soft Tissue Sarcoma Market Segmentation-8 Major Markets
- 11.1 Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
- 11.1.1 Market Overview
- 11.1.2 Radiation Therapy
- 11.1.3 Anti-Angiogenesis
- 11.1.4 Chemotherapy
- 11.1.5 Targeted Therapy
- 11.1.6 Others
- 11.2 Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
- 11.2.1 Market Overview
- 11.2.2 Oral
- 11.2.3 Parenteral
- 11.2.4 Others
- 11.3 Soft Tissue Sarcoma Market (2017-2032) by End Users
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Homecare
- 11.3.4 Specialty Clinics
- 11.3.5 Others
- 11.4 Soft Tissue Sarcoma Market (2017-2032) by Distribution Channel
- 11.4.1 Market Overview
- 11.4.2 Hospital Pharmacy
- 11.4.3 Retail Pharmacy
- 11.4.4 Online pharmacy
- 11.4.5 Others
- 11.5 Soft Tissue Sarcoma Market (2017-2032) by Region
- 11.5.1 Market Overview
- 11.5.2 United States
- 11.5.3 EU-4 and the United Kingdom
- 11.5.3.1 Germany
- 11.5.3.2 France
- 11.5.3.3 Italy
- 11.5.3.4 Spain
- 11.5.3.5 United Kingdom
- 11.5.4 Japan
- 11.5.5 India
- 12 United States Soft Tissue Sarcoma Market (2017-2032)
- 12.1 United States Soft Tissue Sarcoma Market Historical Value (2017-2023)
- 12.2 United States Soft Tissue Sarcoma Market Forecast Value (2024-2032)
- 12.3 United States Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
- 12.3.1 Market Overview
- 12.3.2 Radiation Therapy
- 12.3.3 Anti-Angiogenesis
- 12.3.4 Chemotherapy
- 12.3.5 Targeted Therapy
- 12.3.6 Others
- 12.4 Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
- 12.4.1 Market Overview
- 12.4.2 Oral
- 12.4.3 Parenteral
- 12.4.4 Others
- 13 EU-4 and United Kingdom Soft Tissue Sarcoma Market
- 13.1 EU-4 and United Kingdom Soft Tissue Sarcoma Market Historical Value (2017-2023)
- 13.2 EU-4 and United Kingdom Soft Tissue Sarcoma Market Forecast Value (2024-2032)
- 13.3 EU-4 and United Kingdom Soft Tissue Sarcoma Market Overview
- 13.4 EU-4 and United Kingdom Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
- 13.4.1 Market Overview
- 13.4.2 Radiation Therapy
- 13.4.3 Anti-Angiogenesis
- 13.4.4 Chemotherapy
- 13.4.5 Targeted Therapy
- 13.4.6 Others
- 13.5 EU-4 and United Kingdom Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 14 Japan Soft Tissue Sarcoma Market
- 14.1 Japan Soft Tissue Sarcoma Market Historical Value (2017-2023)
- 14.2 Japan Soft Tissue Sarcoma Market Forecast Value (2024-2032)
- 14.3 Japan Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Radiation Therapy
- 14.3.3 Anti-Angiogenesis
- 14.3.4 Chemotherapy
- 14.3.5 Targeted Therapy
- 14.3.6 Others
- 14.4 Japan Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Others
- 15 India Soft Tissue Sarcoma Market
- 15.1 India Soft Tissue Sarcoma Market Historical Value (2017-2023)
- 15.2 India Soft Tissue Sarcoma Market Forecast Value (2024-2032)
- 15.3 India Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Radiation Therapy
- 15.3.3 Anti-Angiogenesis
- 15.3.4 Chemotherapy
- 15.3.5 Targeted Therapy
- 15.3.6 Others
- 15.4 India Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Others
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 JAPAN PMDA
- 16.1.4 India CDSCO
- 16.1.5 Others
- 17 Patent Analysis
- 17.1 Analysis by Type of Patent
- 17.2 Analysis by Publication year
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Patent Age
- 17.5 Analysis by CPC Analysis
- 17.6 Analysis by Patent Valuation
- 17.7 Analysis by Key Players
- 18 Grants Analysis
- 18.1 Analysis by year
- 18.2 Analysis by Amount Awarded
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Grant Application
- 18.5 Analysis by Funding Institute
- 18.6 Analysis by NIH Departments
- 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Funding and Investment Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 Endo International PLC
- 22.1.1 Financial Analysis
- 22.1.2 Product Portfolio
- 22.1.3 Demographic Reach and Achievements
- 22.1.4 Mergers and Acquisition
- 22.1.5 Certifications
- 22.2 Dr. Reddy's Laboratories Ltd
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisition
- 22.2.5 Certifications
- 22.3 Lupin
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Mergers and Acquisition
- 22.3.5 Certifications
- 22.4 Aurobindo Pharma
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Mergers and Acquisition
- 22.4.5 Certifications
- 22.5 Sun Pharmaceutical Industries Ltd.
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Mergers and Acquisition
- 22.5.5 Certifications
- 22.6 Merck & Co.
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Mergers and Acquisition
- 22.6.5 Certifications
- 22.7 Lilly
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Mergers and Acquisition
- 22.7.5 Certifications
- 22.8 Bayer AG
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Mergers and Acquisition
- 22.8.5 Certifications
- 22.9 Novartis AG
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Mergers and Acquisition
- 22.9.5 Certifications
- 22.10 GlaxoSmithKline PLC
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisition
- 22.10.5 Certifications
- 22.11 Pfizer Inc
- 22.11.1 Financial Analysis
- 22.11.2 Product Portfolio
- 22.11.3 Demographic Reach and Achievements
- 22.11.4 Mergers and Acquisition
- 22.11.5 Certifications
- 22.12 Sanofi
- 22.12.1 Financial Analysis
- 22.12.2 Product Portfolio
- 22.12.3 Demographic Reach and Achievements
- 22.12.4 Mergers and Acquisition
- 22.12.5 Certifications
- 22.13 Teva Pharmaceutical Industries Ltd.
- 22.13.1 Financial Analysis
- 22.13.2 Product Portfolio
- 22.13.3 Demographic Reach and Achievements
- 22.13.4 Mergers and Acquisition
- 22.13.5 Certifications
- 22.14 Mylan N.V.
- 22.14.1 Financial Analysis
- 22.14.2 Product Portfolio
- 22.14.3 Demographic Reach and Achievements
- 22.14.4 Mergers and Acquisition
- 22.14.5 Certifications
- 22.15 F. Hoffmann-La Roche Ltd.
- 22.15.1 Financial Analysis
- 22.15.2 Product Portfolio
- 22.15.3 Demographic Reach and Achievements
- 22.15.4 Mergers and Acquisition
- 22.15.5 Certifications
- List not exhaustive
- 23 Soft Tissue Sarcoma Market - Distribution Model (Additional Insight)
- 23.1 Overview
- 23.2 Potential Distributors
- 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Company Competitiveness Analysis (Additional Insight)
- 25.1 Very Small Companies
- 25.2 Small Companies
- 25.3 Mid-Sized Companies
- 25.4 Large Companies
- 25.5 Very Large Companies
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.